Scientific Articles COVID-19 articles

Es posible esterilizar las máscaras N95 y los barbijos quirúrgicos

Is the Booster Dose Against COVID-19 Effective for All Ages?

Is the Booster Dose Against COVID-19 Effective for All Ages?

The answer is incontrovertible: it is undeniably effective. For all ages, the confirmed COVID19 and severe case rates were significantly lower for patients who had received the BNT162b2 (Pfizer/BioNTech) booster dose vs individuals with only two shots.  After the initial promising results of the mRNA COVID-19 vaccine booster dose given to +60 men and women, Israel

Eficacia de la 3ª dosis de Pfizer contra Omicron

Pfizer Booster Dose Efficacy against Omicron

The BNT162b2 vaccine (Pfizer/BioNTech) has previously shown a 95% efficacy against COVID-19. This efficacy has been changing with the surge of new variants and, at present, its effectiveness against the Omicron variant ─ currently the most prevalent ─ remains unknown. To carry out this study, researchers compared serum samples obtained from participants who had received

Síntomas persistentes post COVID-19: mucho más frecuentes de lo que creíamos

Once Again, the Omicron Variant Tests the Limits of Healthcare Systems, But with Hope

The latest significant COVID-19 variant, the Omicron, is again pushing healthcare systems around the world onto the verge of collapse, having reached over 300 million cases globally (even though the tally has been slowing down).    The vaccine continues to offer hope and, in France for instance, president Macron has doubled their efforts to vaccinate the

The Most Read Articles of 2021: COVID-19

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on COVID-19. Follow us to keep up to date. The Most Read Articles of 2021: COVID-19 01- Efficacy of the Sinopharm Vaccine Against COVID-19 Vaccines developed with two different inactivated strains of SARS-CoV-2 (Sinopharm) significantly reduced

terapia antitrombótica triple

Are Antithrombotics Necessary in Outpatients after COVID-19?

According to this recent study (soon to be published in JAMA), antithrombotic therapy has no clinical benefits for outpatients with stable symptoms of COVID-19.  Both aspirin and apixaban in therapeutic or prophylactic doses did not reduce major cardiovascular events compared against placebo, though these events are rare, which makes it difficult to show any benefit. 

Recomendaciones de la ACC con el nuevo coronavirus

Reasons Behind Increased COVID-19 Infections in a Highly Vaccinated Population

In December 2020, the healthcare workforce at San Diego University saw an unexpected increase in COVID-19 infections. Concurrently, this same month, one of the most ambitious vaccination campaigns ever was taking off, one which managed to inoculate 76% of the population by March 2021 and 87% by June same year.  Infections saw a significant reduction

Síntomas persistentes post COVID-19: mucho más frecuentes de lo que creíamos

New Evidence in Israel in Favor of Applying a Third Dose against COVID-19

According to this study carried out in Israel, patients over 60 who had received two doses against COVID-19 at least 5 months ago will benefit from an additional dose in terms of a significant reduction of severe disease. In addition, patients who unfortunately got severely ill despite receiving a third shot, were more easily managed. 

SOLACI-CACI 2021 Virtual

SOLACI-CACI 2021 | Cardiovascular Disease Management and Cath Lab During the COVID-19 Pandemic

✔️ Watch again the session on Cardiovascular Disease Management and Cath Lab During the COVID-19 Pandemic in the SOLACI-CACI 2021 Congress. 👨‍🏫 Program: 04:55 – Thromboembolic Complications in COVID – José Ceresetto 27:59 – Global Registry of Acute Myocardial Infarction of Primary PCI in COVID Era – Giuseppe De Luca 53:36 – Infectious Disease Care in

ESC 2021 | Injuria aguda y crónica por COVID-19 y su impacto en la mortalidad

ESC 2021 | Acute and Chronic Myocardial Injury in COVID-19 Patients and Impact in Mortality

In patients hospitalized for COVID-19, both acute and chronic myocardial injury impact survival at 6 months. In addition, the risk does not disappear after the acute phase of the disease, instead it persists in the following months among those who survive.  This study was presented at the scientific sessions of ESC 2021 and was simultaneously

Historia natural de la infección asintomática por COVID-19

Vaccine Efficacy against the Delta COVID-19 Variant

COVID-19 B.1.617.2 (delta) Variant, first detected in India, has contributed to a significant increase in the number of COVID cases and has inexorably spread all across the world.  The relative efficacy of BNT162b2 (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (AstraZeneca) vaccines against this new variant was unclear Vaccine efficacy against the delta symptomatic infection vs. the predominant

Síntomas persistentes post COVID-19: mucho más frecuentes de lo que creíamos

Heparin Anticoagulation in Critically Ill COVID-19 Patients: Results that Differ from the Rest

In critically ill COVID-19 patients, an initial strategy of anticoagulation with heparin did not result in any benefit compared with standard prophylactic treatment. Thrombosis and inflammation are the main issues when discussing COVID-19 related morbidity. This led to testing whether an anticoagulation scheme could improve prognosis in critically ill COVID-19 patients. Given the dynamics of